Long Shortz with Racura Oncology: Investor insight into Racura’s patent breakthrough

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully about the company’s major scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound. 

Dr Tillett explains why composition of matter patents are considered the gold standard in biotech IP, critical for securing future licensing and acquisition interest from major pharma players.

Watch the full video here.